Loading viewer...
investor_presentation
Format: PDF investor_presentation
© 2020 Tonix Pharmaceuticals Holding Corp.1 February 2020 Version P0221 2-8 -20 (Doc 0598)Investor Presentation
© 2020 Tonix Pharmaceuticals Holding Corp.1
Version P0221 2-8 -20 (Doc 0598)Investor Presentation
© 2020 Tonix Pharmaceuticals Holding Corp.2Cautionary Note on Forward -Looking Statements
Certain statements inthispresentation regarding strategic plans, expectations andobjectives forfuture
operations orresults are“forward -looking statements” asdefined bythePrivate Securities Litigation Reform
Actof1995.These statements may beidentified bytheuseofforward -looking words such as“anticipate,”
“believe,” “forecast,” “estimate” and“intend,” among others .These forward -looking statements arebased on
Tonix’s current expectations andactual results could differ materially .There areanumber offactors that
could cause actual events todiffer materially from those indicated bysuch forward -looking statements. These
factors include, butarenotlimited to,risks related tofailure toobtain U.S.Food andDrug Administration
clearances orapprovals andnoncompliance withitsregulations ;ourneed foradditional financing ;substantial
competition ;uncertainties ofpatent protection andlitigation ;uncertainties ofgovernment orthird party payor
reimbursement ;limited research anddevelopment efforts anddependence upon third parties .Aswithany
pharmaceutical under development, there aresignificant risks inthedevelopment, regulatory approval and
commercialization ofnewproducts .Theforward -looking statements inthispresentation aremade asofthe
date ofthispresentation, even ifsubsequently made available byTonix onitswebsite orotherwise .Tonix
does notundertake anobligation toupdate orrevise anyforward -looking statement, except asrequired by
law.Investors should read theriskfactors setforth intheAnnual Report onForm 10-Kfortheyear ended
December 31,2018, asfiledwiththeSecurities andExchange Commission (the“SEC”) onMarch 18,2019,
andperiodic reports andcurrent reports filedwiththeSEConorafter thedatethereof .AllofTonix's forward -
looking statements areexpressly qualified byallsuch riskfactors andother cautionary statements .© 2020 Tonix Pharmaceuticals Holding Corp.3Tonix Pharmaceuticals: Lead Program
In Phase 3 clinical development of TNX -102 SL1for Fibromyalgia
•Chronic pain condition
Fibromyalgia milestones ( Phase 3 RELIEF study ):
•3rdQuarter 2020 -Interim analysis results expected
•1stHalf 2021 -Topline data expected
1 TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication© 2020 Tonix Pharmaceuticals Holding Corp.4CNS Candidates in Clinical Development
Pain, Psychiatry and Addiction
Phase 2 NDA2/BLA3Market Pipeline Product Indication Phase 3
Daytime treatment for PTSDTNX- 601 CR6TNX- 13005
Preview truncated — download the full document for the complete content.
investor_presentation
48 Pages
investor_presentation
66 Pages
National Fuel Gas Company